Bubs Australia (BUB) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
23 Nov, 2025Executive summary
Achieved FY25 revenue of $102.5M, surpassing the $100M target, with 29% year-over-year growth driven by strong demand in key markets, especially the USA.
Positive underlying EBITDA of $0.6M, a turnaround from a $20.3M loss in FY24, reflecting improved margin and cost control.
Delivered positive operating cash flow of $6.1M and net assets of $42.5M, supported by disciplined working capital management.
New CEO with 30+ years in consumer products and dairy, focused on people, partners, and business performance.
Strategic focus on operational resilience, long-term profitability, and working capital benefits.
Financial highlights
Revenue increased 29% year-over-year to $102.5M, with the USA contributing 52% of total revenue.
Gross profit margin at 48%, surpassing the 40% commitment.
Underlying EBITDA positive at $0.6M; baseline EBITDA $5.5M, a turnaround from $20.3M loss in FY24.
Positive operating cash flow of $6.1M, a $32.4M improvement over prior year.
Cash and cash equivalents at $17.4M, with all borrowings repaid and full $10M facility available.
Outlook and guidance
Strategy update planned for late November 2025 to map out full potential and resource alignment.
Expectation to rebuild inventories in early FY26, impacting operating cash flow in the first half.
Gross margin expected to normalize at 40%-45% as tariffs and potential air freight are absorbed.
Continued investment in marketing, especially in the U.S., to drive brand equity and customer acquisition.
Latest events from Bubs Australia
- FY26 revenue guidance raised to $120–125M with double-digit growth and strong EBITDA outlook.BUB
Status update26 Mar 2026 - Revenue up 14% to $55.5M, led by US growth; gross margin 48%; FY26 outlook upgraded.BUB
H1 202627 Feb 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025